|Bid||2.1600 x 2200|
|Ask||2.4000 x 1100|
|Day's Range||2.1600 - 2.3100|
|52 Week Range||2.1600 - 11.9600|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Savara Inc. , an orphan lung disease company, today announced that the Company's Chief Operating Officer, Taneli Jouhikainen, will present at the Canaccord Genuity Global Growth Conference on Wednesday, August 7, 2019 at 11:30 a.m.
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
Savara Inc. , an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m.
were crumbling Thursday, falling more than 75% after the company announced that its lung disease treatment candidate Molgradex failed its Phase 3 study. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer. The company said that was meeting with the Food and Drug Administration and the European Medicines Agency to discuss the results of the study and to determine its next course of action.
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
crumpled in after-hours trading Wednesday after the company said a phase 3 trial of its Molgradex drug treatment for a rare lung disease had failed to meet its test goals. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer.
Shares in Savara Inc. , which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target. Savara said a phase 3 study of core pipeline drug Molgradex, which seeks to treat Autoimmune Alveolar Pulmonary Proteinosis, did not meet its primary endpoint. Secondary endpoints were met, and the company said it is figuring out next steps. "We are preparing to meet with the FDA and EMA to discuss the results from this study and to determine our options to seek approval based on the current data, and potentially conduct an additional study incorporating the learnings," Chief Executive Rob Neville said in a statement. Shares were halted ahead of the announcement, after closing at $10.57, which gave the company a market cap of nearly $380 million. When shares were reopened for late trading, the price immediately fell to less than $2.40.
Savara Inc. (SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP. An average A-aDO2 improvement of 12.1 mmHg was observed in the continuous dosing arm, compared to an average A-aDO2 improvement of 8.8 mmHg in the placebo arm. With an estimated 4.6 mmHg treatment difference (p=0.17), the study did not meet its primary endpoint.
Savara Inc (SVRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Savara Inc. (SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Molgradex, the Company’s lead product candidate, is being investigated in a pivotal Phase 3 study, called IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). Topline results from the study are expected in June 2019.
Savara Inc. , an orphan lung disease company, today announced that the Company will report first quarter 2019 financial results and provide a business update on Thursday, May 9, 2019.
AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at the H.C. Wainwright Global ...
AUSTIN, TX / ACCESSWIRE / April 1, 2019 / Savara Inc. (SVRA), an orphan lung disease company, today announced the initiation of ENCORE, a Phase 2a clinical study evaluating its lead product candidate, Molgradex, for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and is also currently in Phase 2a development for NTM in non-CF patients and in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). "People living with CF who have chronic NTM lung infection are in need of improved treatment options to complement current antibiotic regimens," said Rob Neville, Chief Executive Officer.
AUSTIN, TX / ACCESSWIRE / March 13, 2018 / Savara Inc. (SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2018 and provided a business update. ''With the approaching data read-out from our pivotal IMPALA study, we enter 2019 with confidence,'' said Rob Neville, Chief Executive Officer, Savara. ''We've started key commercial preparation activities to support a potential launch as we believe Molgradex could transform the standard-of-care for a debilitating disease with no approved therapies.